1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

LevelStock.com: Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference

Investors seeking technical and fundamental stock alerts on penny stocks can subscribe to our newsletters today at LevelStock.com

 
PRLog - Feb. 4, 2010 - Braintree,Ma. LevelStock.com  is pleased to announce today 4th Feb 2010, to all of its members and investors information on Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) The Company released news Feb 3rd as follows:

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that Arthur T. Sands, M.D., Ph.D., Lexicon’s president and chief executive officer, will present at the 2010 BIO CEO & Investor Conference in New York on Monday, February 8, 2010 at 9:30 a.m., Eastern Time. The conference is hosted by the Biotechnology Industry Organization (BIO) and will take place from February 8-9, 2010.

About BIO CEO & Investor Conference

The BIO CEO & Investor Conference is the largest independent investor conference focused on publicly-traded biotechnology companies. The conference provides a forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry through issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, and one-on-one meetings.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease.  Lexicon currently has five drug candidates in development for autoimmune disease, carcinoid syndrome, diabetes, glaucoma and irritable bowel syndrome, all of which were discovered by Lexicon’s research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon’s ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under “Factors Affecting Forward-Looking Statements” and “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2008, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

About LevelStock.com

We are an investor community and investors relations website specializing in emerging growth stocks in today’s Hot Sectors and providing a platform of services for SmallCap, MicroCap, NanoCap Companies.

We encourage everyone to join our social media sites:

Free Subscription For Our Newsletters:  http://www.levelstock.com/

FaceBook: http://www.facebook.com/group.php?gid=283660480870

Twitter: http://twitter.com/levelstock

LevelStock.com is not a registered investment advisor or broker-dealer. The information here is believed to be reliable, but not guaranteed to be accurate by LevelStock.com Please be advised that the information contained may or may not be complete and is solely for informational purposes only. Please read our full disclaimer for complete risks and disclosures http://levelstock.bondwaresite.com/news.php?viewStory=19

CONTACT INFO: LevelStock.com 288 Grove Street Suite 181, Braintree, MA 02184

Email: support@levelstock.com

--- End ---

Click to Share

Contact Email:
***@levelstock.com Email Verified
Source:LevelStock.com
Industry:Biotech, Medical, Finance
Tags:autoimmune disease, biopharmaceutical, biotechnology, carcinoid syndrome, Diabetes, glaucoma, irritable bowel syndrome
Shortcut:prlog.org/10518539
Verified Account Email Address

Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share